The global Crohn’s disease drugs market is anticipated to grow at a significant CAGR during the forecast period (2024-2031). The major factors that are expected to accelerate the growth of the market include the increasing incidence of inflammatory bowel syndrome, such as Crohn’s disease and ulcerative colitis. This is boosting the demand for anti-inflammatory drugs for the treatment of Crohn’s disease. Some kinds of anti-inflammatory medications that are used used to treat Crohn’s disease include 5 aminosalicylic acid (5-ASA) compounds, such as mesalamine (Pentasa, Canasa suppository) and sulfasalazine (Azulfidine). These work in direct contact or they can be applied topically with the inflamed tissue which makes healing effective.
Get Free Sample link @ https://www.omrglobal.com/request-sample/Crohns-disease-drugs-market
Another factor that is creating a positive impact on this segment is the fact that there is no permanent cure for Crohn’s disease. Technically, Crohn’s disease has no permanent cure and therefore patients suffering from this particular disease and its associated conditions have to depend on anti-inflammatory and other drugs to obtain relief. Crohn’s disease is a type of inflammatory bowel disease (IBD). It causes inflammation of digestive tract, which can lead to abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. Inflammation caused by Crohn’s disease can involve different areas of the digestive tract in different people. This inflammation often spreads into the deeper layers of the bowel.
Crohn’s disease drug manufacturers are focusing on the commercial distribution of medicines through retail pharmacies and online portals. These channels widely distribute anti-inflammatory drugs and corticosteroids with and/or without prescription. Consumers can also avail of discounts on bulk purchases of medicines through online portals. Therefore, easy product availability, as well as price discounts, contribute significantly to the growth of the market. Further, in order to maintain a strong position in the market, the market players are adopting various strategic moves, such as product launches, partnerships and collaborations, and mergers and acquisitions. In September 2021, AbbVie, Inc. ABBV announced that it has submitted a regulatory application in the US, seeking approval for its interleukin-23 (“IL-23”) inhibitor Skyrizi (risankizumab) as a potential treatment for moderate to severe Crohn’s disease (CD). It seeks approval for Skyrizi both as a 600mg intravenous (“IV”) induction and 360mg subcutaneous maintenance therapy in patients aged 16 years and older with CD.
Full report of Crohn’s Disease Drugs Market available @ https://www.omrglobal.com/industry-reports/Crohns-disease-drugs-market
Market Coverage
- Segment Covered-
- By Drug Type
- By Route of Administration
- Regions covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape: Allergan plc, AbbVie Inc., and Pfizer Inc., among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Crohn’s Disease Drugs Market Report by Segment
By Drug Type
- Anti-Inflammatory
- Immune System Suppressors
- Antibiotics
- Others
By Route of Administration
- Oral
- Injectable
Reasons to Buying From us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/Crohns-disease-drugs-market
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
